TAIPEI: First shared at a recent Japanese Society of Digital Pathology meeting, the company is forging a global alliance with a leading US medical institution and other organizations to harness technology for better patient care and outcomes in oncology. TAIPEI, Jan. 22, 2025 /PRNewswire/ — JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, is unveiling its vision for AI and 3D digital pathology to advance patient-centered care. The vision was first detailed publicly by Dr. Yen-Yin Lin, CEO of JelloX, during the August 2024 Annual Meeting of the Japanese Society of Digital Pathology. JelloX continues to distinguish itself as an early adopter of AI and 3D imaging applied to cancer pathology.